8,007 Shares in Stryker Corporation $SYK Acquired by Stillwater Wealth Management Group

Stillwater Wealth Management Group acquired a new stake in Stryker Corporation (NYSE:SYK) in the 3rd quarter, HoldingsChannel.com reports. The fund acquired 8,007 shares of the medical technology company’s stock, valued at approximately $2,960,000. Stryker accounts for about 2.1% of Stillwater Wealth Management Group’s portfolio, making the stock its 23rd biggest position.

A number of other hedge funds have also recently added to or reduced their stakes in SYK. Investment Research Partners LLC bought a new stake in shares of Stryker during the third quarter worth $423,000. Cambria Investment Management L.P. bought a new position in shares of Stryker in the 3rd quarter valued at $223,000. Alexander Labrunerie & CO. Inc. bought a new position in shares of Stryker in the 3rd quarter valued at $256,000. Greenfield Seitz Capital Management LLC boosted its holdings in shares of Stryker by 5.3% during the 3rd quarter. Greenfield Seitz Capital Management LLC now owns 2,739 shares of the medical technology company’s stock valued at $1,013,000 after acquiring an additional 137 shares in the last quarter. Finally, Petix & Botte Co boosted its holdings in shares of Stryker by 10.0% during the 3rd quarter. Petix & Botte Co now owns 946 shares of the medical technology company’s stock valued at $350,000 after acquiring an additional 86 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Down 1.0%

Shares of NYSE:SYK opened at $345.64 on Thursday. The firm has a market cap of $132.27 billion, a P/E ratio of 41.15, a P/E/G ratio of 2.04 and a beta of 0.85. Stryker Corporation has a 12-month low of $328.23 and a 12-month high of $404.87. The business has a fifty day simple moving average of $364.43 and a 200 day simple moving average of $366.61. The company has a quick ratio of 1.21, a current ratio of 1.89 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 EPS for the quarter, beating analysts’ consensus estimates of $4.40 by $0.07. The firm had revenue of $7.17 billion for the quarter, compared to analyst estimates of $7.12 billion. Stryker had a return on equity of 24.41% and a net margin of 12.92%.The business’s revenue was up 11.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $4.01 EPS. Analysts predict that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be issued a $0.88 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $3.52 annualized dividend and a yield of 1.0%. Stryker’s dividend payout ratio is presently 41.90%.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of the stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the completion of the sale, the director owned 2,457,331 shares of the company’s stock, valued at approximately $891,814,566.52. This represents a 9.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 5.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. TD Cowen cut Stryker from a “buy” rating to a “hold” rating and set a $387.00 target price for the company. in a report on Monday, January 26th. Citizens Jmp raised Stryker from a “market perform” rating to an “outperform” rating and set a $440.00 price target on the stock in a research note on Friday, December 19th. Citigroup restated a “market outperform” rating on shares of Stryker in a report on Friday, January 30th. Raymond James Financial raised Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 price objective for the company in a research note on Tuesday, January 6th. Finally, Robert W. Baird set a $437.00 price objective on shares of Stryker in a report on Friday, January 30th. Fourteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $427.50.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.